DRUG NEWS: More restrictions announced for acne drug

October 2005 
Volume 35  Number 10
Pages 30 - 30
  PDF Version Available!

 Under a new FDA program, everyone prescribing, taking, selling, or dispensing the acne drug isotretinoin (Accutane) will be required to enroll in a national registry by the end of the year. The iPLEDGE program is intended to ensure that health care professionals and patients understand the drug's serious risks—miscarriage, severe birth defects, depression, and suicidal thoughts—and take appropriate precautions, including avoiding pregnancy. Notorious for causing birth defects, isotretinoin has long been under fire by the March of Dimes and other advocacy groups who want it tightly controlled or taken off the market altogether.

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

Featured Jobs

Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member